DE69905716D1 - Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm - Google Patents

Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm

Info

Publication number
DE69905716D1
DE69905716D1 DE69905716T DE69905716T DE69905716D1 DE 69905716 D1 DE69905716 D1 DE 69905716D1 DE 69905716 T DE69905716 T DE 69905716T DE 69905716 T DE69905716 T DE 69905716T DE 69905716 D1 DE69905716 D1 DE 69905716D1
Authority
DE
Germany
Prior art keywords
water
size range
new process
insoluble components
producing particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69905716T
Other languages
English (en)
Other versions
DE69905716T2 (de
Inventor
W Pace
Michael Vachon
Awadhesh Mishra
B Henriksen
Val Krukonis
Anthony Godinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skyepharma Canada Inc
Original Assignee
Skyepharma Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyepharma Canada Inc filed Critical Skyepharma Canada Inc
Publication of DE69905716D1 publication Critical patent/DE69905716D1/de
Application granted granted Critical
Publication of DE69905716T2 publication Critical patent/DE69905716T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/50—Mixing liquids with solids
    • B01F23/51—Methods thereof
    • B01F23/511—Methods thereof characterised by the composition of the liquids or solids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/20—Jet mixers, i.e. mixers using high-speed fluid streams
    • B01F25/28—Jet mixers, i.e. mixers using high-speed fluid streams characterised by the specific design of the jet injector
    • B01F25/281—Jet mixers, i.e. mixers using high-speed fluid streams characterised by the specific design of the jet injector the jet injector being of the explosive rapid expansion of supercritical solutions [RESS] or fluid injection of molecular spray [FIMS] type, i.e. the liquid is jetted in an environment (gas or liquid) by nozzles, in conditions of significant pressure drop, with the possible generation of shock waves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/04—Specific aggregation state of one or more of the phases to be mixed
    • B01F23/043—Mixing fluids or with fluids in a supercritical state, in supercritical conditions or variable density fluids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/50—Mixing liquids with solids
    • B01F23/56—Mixing liquids with solids by introducing solids in liquids, e.g. dispersing or dissolving
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
DE69905716T 1998-06-19 1999-06-18 Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm Expired - Lifetime DE69905716T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8985298P 1998-06-19 1998-06-19
US89852P 1998-06-19
PCT/US1999/013755 WO1999065469A2 (en) 1998-06-19 1999-06-18 Processes to generate submicron particles of water-insoluble compounds

Publications (2)

Publication Number Publication Date
DE69905716D1 true DE69905716D1 (de) 2003-04-10
DE69905716T2 DE69905716T2 (de) 2004-02-05

Family

ID=22219900

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69905716T Expired - Lifetime DE69905716T2 (de) 1998-06-19 1999-06-18 Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm

Country Status (14)

Country Link
US (1) US6177103B1 (de)
EP (1) EP1089714B1 (de)
JP (2) JP4693238B2 (de)
KR (1) KR100622047B1 (de)
CN (1) CN1160059C (de)
AT (1) ATE233549T1 (de)
AU (2) AU755993C (de)
CA (1) CA2335472C (de)
DE (1) DE69905716T2 (de)
ES (1) ES2194477T3 (de)
HK (1) HK1039566A1 (de)
IL (2) IL140276A0 (de)
SE (1) SE521255C2 (de)
WO (1) WO1999065469A2 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
WO2001024917A1 (en) * 1999-10-07 2001-04-12 Battelle Memorial Institute Method and apparatus for obtaining a suspension of particles
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
WO2001045731A1 (en) * 1999-12-21 2001-06-28 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
AU2001247244B2 (en) * 2000-02-28 2005-06-02 Genesegues, Inc. Nanocapsule encapsulation system and method
PT1263413E (pt) * 2000-03-09 2006-08-31 Univ Ohio State Res Found Metodo de preparacao de dispersoes solidas
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US6541542B2 (en) * 2000-09-29 2003-04-01 Eastman Chemical Company Process for production of polymeric powders
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
CN1525999A (zh) 2001-07-12 2004-09-01 ��˹���´﹫˾ 压缩流体配方
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2475092C (en) * 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US7186796B2 (en) 2002-02-25 2007-03-06 Phasex Corporation Method for drying water-borne materials
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
ES2381970T3 (es) * 2002-04-15 2012-06-04 Map Pharmaceuticals Inc Formulación de partículas finas que usan gases licuados o densos
FR2838356B1 (fr) * 2002-04-15 2004-05-28 Separex Sa Procede d'obtention d'une suspension stable de particules dans un liquide
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1531799A1 (de) * 2002-06-10 2005-05-25 Elan Pharma International Limited Pharmazeutische nanopartikel-formulierungen mit hmg-coa-reduktase-inhibitoren ("statine"), neue kombinationen davon sowie herstellung dieser pharmazeutischen zusammensetzungen
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
CN1310648C (zh) 2002-12-13 2007-04-18 佳高泰克有限公司 局部纳米颗粒螺甾内酯制剂
GB0229714D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel apparatus and method
JPWO2005013938A1 (ja) * 2003-08-06 2006-09-28 エーザイ株式会社 薬物超微粒子の製造法及び製造装置
WO2005053851A1 (en) * 2003-11-26 2005-06-16 E.I. Dupont De Nemours And Company High pressure media milling system and process of milling particles
US7582275B1 (en) 2004-01-26 2009-09-01 The United States Of America As Represented By The Secretary Of The Air Force Method of processing filamentary nanocarbon
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
EP1711163A2 (de) * 2004-02-05 2006-10-18 Baxter International Inc. Unter verwendung von selbststabilisierenden mitteln hergestellte dispersionen
JP5138362B2 (ja) * 2004-03-23 2013-02-06 ノバルティス アーゲー 医薬組成物
GB0406515D0 (en) * 2004-03-23 2004-04-28 Novartis Ag Organic compounds
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
EP1731138B1 (de) * 2004-03-31 2016-03-23 Toyama Chemical Co., Ltd. Feine dispersion eines schwerlöslichen arzneimittels und herstellungsverfahren dafür
US7754243B2 (en) 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US7293570B2 (en) * 2004-12-13 2007-11-13 Cool Clean Technologies, Inc. Carbon dioxide snow apparatus
ES2265262B1 (es) * 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
KR20140002810A (ko) * 2005-05-05 2014-01-08 사노피-아벤티스 유.에스. 엘엘씨 안정한 나노입자 제형
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
EP1906973A2 (de) * 2005-06-14 2008-04-09 Baxter International Inc. Pharmazeutische formulierungen zur minimierung von arzneimittel-wechselwirkungen
JP2007007524A (ja) * 2005-06-29 2007-01-18 Kagawa Industry Support Foundation 超臨界溶液急速冷却法による単分散超微粒子の製造方法及び装置
WO2007009986A2 (en) * 2005-07-19 2007-01-25 Activery Biotech, S.L. Process for obtaining a composite
ES2292300B1 (es) * 2005-07-19 2009-02-16 Sociedad Española De Carburos Metalicos, S.A.(Titular Al 50%) Procedimiento para la obtencion de un material compuesto.
US7608461B1 (en) * 2005-09-16 2009-10-27 Sandia Corporation Surface engineered nanoparticles for improved surface enhanced Raman scattering applications and method for preparing same
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
ZA200804379B (en) * 2005-12-16 2009-09-30 Unilever Plc Surface-active material and its application
KR20090045205A (ko) * 2006-06-26 2009-05-07 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 활성제 제형 및 이의 제조방법 및 사용방법
BRPI0715234A2 (pt) * 2006-10-17 2013-06-25 Unilever Nv produtos alimentÍcios aerados, processo para a preparaÇço de um produto alimentÍcio aerado e processo para a preparaÇço de um produto alimentÍcio estabilizado
EP2073644A1 (de) * 2006-10-17 2009-07-01 Unilever N.V. Tiefgefrorene geschäumte nahrungsmittelprodukte, die oberflächenaktive fasern enthalten
BRPI0718390A2 (pt) * 2006-10-17 2013-11-26 Unilever Nv Composição alimentícia compreendendo bolhas de gás e processo para prepará-la.
US20100291280A1 (en) * 2006-10-17 2010-11-18 Theodorus Berend Jan Blijdenstein Food composition comprising gas bubbles and process for preparing it
ZA200901780B (en) * 2006-10-17 2010-06-30 Unilever Plc Food composition comprising gas bubbles and process for preparing it
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
JP5004333B2 (ja) * 2006-12-08 2012-08-22 日機装株式会社 ナノオーダ粒子製造装置
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
EP2231169B1 (de) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
KR20180056816A (ko) 2009-05-11 2018-05-29 베르그 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
AU2011224207B2 (en) 2010-03-12 2015-11-19 Berg Llc Intravenous formulations of Coenzyme Q10 (CoQ10) and methods of use thereof
PL2550092T3 (pl) 2010-03-22 2019-01-31 Instillo Gmbh Sposób wytwarzania mikro- lub nanocząstek
US20120269867A1 (en) 2011-04-04 2012-10-25 Jimenez Joaquin J Methods of treating central nervous system tumors
PE20140628A1 (es) 2011-06-17 2014-05-30 Berg Llc Composiciones farmaceuticas inhalables
EP2766018A4 (de) * 2011-10-13 2015-02-25 Univ Case Western Reserve Rxr-agonisten-verbindungen und verfahren dafür
CN104394850A (zh) 2012-02-16 2015-03-04 布莱特赛德创新有限公司 膳食和营养组合物及应用的方法
EA028302B1 (ru) 2013-03-28 2017-10-31 Инстилло Гмбх Устройство и способ для изготовления дисперсий и твёрдых фаз
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
KR20170054429A (ko) 2014-09-03 2017-05-17 제네세규스 인코포레이티드 치료용 나노입자 및 관련 조성물, 방법, 및 시스템
FI20140266A (fi) 2014-10-06 2016-04-07 Nanoform Finland Oy Menetelmä ja laite nanopartikkeleiden valmistamiseksi
CN110115952B (zh) * 2018-02-05 2021-10-15 绍兴吉能纳米科技有限公司 一种可使用低温液化气体的高压均质方法
WO2020234448A1 (en) 2019-05-23 2020-11-26 Helm Ag Nanoparticles comprising enzalutamide
JP7237183B2 (ja) * 2019-10-16 2023-03-10 株式会社 ナノ・キューブ・ジャパン 難溶性物質の超微粒子の分散液の製造方法
EP3884930A1 (de) 2020-03-23 2021-09-29 Bayer AG Nano-trockenschmelze

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998753A (en) * 1974-08-13 1976-12-21 Hoffmann-La Roche Inc. Water dispersible carotenoid preparations and processes thereof
SI9400079B (sl) * 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
EP0925061B1 (de) 1996-08-22 2005-12-28 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen stoffen und verfahren zu deren herstellung
CA2326349A1 (en) 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants

Also Published As

Publication number Publication date
KR20010053041A (ko) 2001-06-25
WO1999065469A3 (en) 2000-03-02
EP1089714B1 (de) 2003-03-05
SE0004620L (sv) 2001-02-08
JP2002518318A (ja) 2002-06-25
JP4693238B2 (ja) 2011-06-01
KR100622047B1 (ko) 2006-09-07
US6177103B1 (en) 2001-01-23
AU755993C (en) 2003-10-30
CN1312708A (zh) 2001-09-12
WO1999065469A2 (en) 1999-12-23
ES2194477T3 (es) 2003-11-16
AU755993B2 (en) 2003-01-02
IL140276A0 (en) 2002-02-10
IL140276A (en) 2007-07-24
SE521255C2 (sv) 2003-10-14
DE69905716T2 (de) 2004-02-05
HK1039566A1 (zh) 2002-05-03
ATE233549T1 (de) 2003-03-15
AU2003203459A8 (en) 2010-04-29
JP2011079839A (ja) 2011-04-21
CN1160059C (zh) 2004-08-04
AU2003203459A1 (en) 2003-06-12
CA2335472C (en) 2008-10-28
SE0004620D0 (sv) 2000-12-14
EP1089714A2 (de) 2001-04-11
CA2335472A1 (en) 1999-12-23
AU4693899A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
DE69905716D1 (de) Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm
ATE328644T1 (de) Oberflächenmodifziertes zinkoxid zur herstellung nanopartikulärer dispersionen
AU2003251349A1 (en) Porous beads and method of production thereof
ATE375370T1 (de) Verfahren zur herstellung einer wässrigen dispersion von aus polymerisat und feinteiligem anorganischem feststoff aufgebauten partikeln
DE60020732D1 (de) Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
ATE457373T1 (de) Verfahren zur herstellung von kolloidale nanokristalle in nicht koordinierenden lösungsmitteln
DE60222695D1 (de) Verfahren zur herstellung von kohlenstoffnanostrukturen
MY128472A (en) Process for producing epoxidized diene polymer.
DE60140625D1 (de) Verfahren zur herstellung von mikropartikeln
BG107522A (en) Expanded perlite products with controlled particle size distribution
BR0204804A (pt) Agente estabilizante de proteìnas para a estabilização de um material protéico em meio ácido aquoso, composição para suspensão em um lìquido ácido aquoso, método de estabilização de proteìnas em um lìquido ácido aquoso e método de formação de uma suspensão estável de material protéico em sucos ácidos
AU2003244123A1 (en) Fluoropolymer dispersion and process for producing fluoropolymer dispersion
ATE340639T1 (de) Verfahren zur herstellung von teilchen
ATE237556T1 (de) Verfahren zur herstellung von silanisierter kolloidaler kieselsäure
DE50110410D1 (de) Adsorbens mit unterschiedlich modifizierten oberflächenbereichen, verfahren zu dessen herstellung und verwendung davon
ATE453441T1 (de) Verfahren zur abtrennung von komponenten aus flüssigen und gasförmigen medien mit nanokompositen
ATE120437T1 (de) Verfahren zur herstellung einer wässerigen kolloidalen dispersion einer cerium-iv-verbindung und hergestellte dispersionen.
HUP0204269A2 (hu) Eljárás pigmentek előállítására
EA199900917A2 (ru) Способ получения монодисперсных гелеобразных анионитов
DE60211772D1 (de) Verfahren zur Herstellung von Proteine
EP1319400A3 (de) Verfahren zur Herstellung von submikronen Partikeln wasserunlöslicher Komponenten
SE0004928D0 (sv) A method for the manufacturing of porous material
PT1177223E (pt) Dispersoes de plastico aquosas que apresentam uma estabilidade mais elevada
BR0110881A (pt) Processo para a preparação de corpos sólidos inorg nicos porosos a partir de uma dispersão aquosa de partìculas, corpos sólidos inorg nicos porosos, e, uso de corpos sólidos inorg nicos porosos
BR0205251A (pt) Composição reticulável, método para fornecer um artigo compreendendo um polìmero reticulável, e, processo para formar uma composição reticulável

Legal Events

Date Code Title Description
8364 No opposition during term of opposition